These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 10960060)
1. Prevention by dexrazoxane of down-regulation of ryanodine receptor gene expression in anthracycline cardiomyopathy in the rat. Burke BE; Gambliel H; Olson RD; Bauer FK; Cusack BJ Br J Pharmacol; 2000 Sep; 131(1):1-4. PubMed ID: 10960060 [TBL] [Abstract][Full Text] [Related]
2. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism. Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089 [TBL] [Abstract][Full Text] [Related]
3. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits. Jirkovský E; Lenčová-Popelová O; Hroch M; Adamcová M; Mazurová Y; Vávrová J; Mičuda S; Šimůnek T; Geršl V; Štěrba M Toxicology; 2013 Sep; 311(3):191-204. PubMed ID: 23831762 [TBL] [Abstract][Full Text] [Related]
4. Persistent effects of doxorubicin on cardiac gene expression. Boucek RJ; Miracle A; Anderson M; Engelman R; Atkinson J; Dodd DA J Mol Cell Cardiol; 1999 Aug; 31(8):1435-46. PubMed ID: 10423342 [TBL] [Abstract][Full Text] [Related]
5. Cholinesterases in dexrazoxane-treated daunorubicin cardiomyopathy in rabbits. Gersl V; Bajgar J; Hrdina R; Mazurová Y; Machácková J; Cerman J; Suba P Gen Physiol Biophys; 1999 Dec; 18(4):335-46. PubMed ID: 10766032 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377 [TBL] [Abstract][Full Text] [Related]
7. Treatment of anthracycline extravasation with dexrazoxane. Langer SW; Sehested M; Jensen PB Clin Cancer Res; 2000 Sep; 6(9):3680-6. PubMed ID: 10999761 [TBL] [Abstract][Full Text] [Related]
8. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Walker UA Br J Pharmacol; 2007 Jul; 151(6):771-8. PubMed ID: 17519947 [TBL] [Abstract][Full Text] [Related]
9. Effect of sodium 2,3-dimercaptopropane-1-sulphonate (DMPS) on chronic daunorubicin toxicity in rabbits: comparison with dexrazoxane. Hrdina R; Gersl V; Klimtová I; Simůnek T; Mazurová Y; Machácková J; Adamcová M Acta Medica (Hradec Kralove); 2002; 45(3):99-105. PubMed ID: 12515046 [TBL] [Abstract][Full Text] [Related]
11. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients. Anderson B Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251 [TBL] [Abstract][Full Text] [Related]
12. Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. Arai M; Tomaru K; Takizawa T; Sekiguchi K; Yokoyama T; Suzuki T; Nagai R J Mol Cell Cardiol; 1998 Feb; 30(2):243-54. PubMed ID: 9515001 [TBL] [Abstract][Full Text] [Related]
13. Cardiac remodeling and MMPs on the model of chronic daunorubicin-induced cardiomyopathy in rabbits. Adamcová M; Potáčová A; Popelová O; Štěrba M; Mazurová Y; Aupperle H; Geršl V Physiol Res; 2010; 59(5):831-836. PubMed ID: 20406046 [TBL] [Abstract][Full Text] [Related]
14. Multiple actions of the anthracycline daunorubicin on cardiac ryanodine receptors. Hanna AD; Janczura M; Cho E; Dulhunty AF; Beard NA Mol Pharmacol; 2011 Sep; 80(3):538-49. PubMed ID: 21697274 [TBL] [Abstract][Full Text] [Related]
15. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. Hofland KF; Thougaard AV; Sehested M; Jensen PB Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593 [TBL] [Abstract][Full Text] [Related]
16. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759 [TBL] [Abstract][Full Text] [Related]
17. Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart. Plandé J; Platel D; Tariosse L; Robert J Toxicol Lett; 2006 Feb; 161(1):37-42. PubMed ID: 16129573 [TBL] [Abstract][Full Text] [Related]
18. Cardioprotective effects of hydroxysafflor yellow A on diabetic cardiac insufficiency attributed to up-regulation of the expression of intracellular calcium handling proteins of sarcoplasmic reticulum in rats. He H; Liu Q; Shi M; Zeng X; Yang J; Wu L; Li L Phytother Res; 2008 Aug; 22(8):1107-14. PubMed ID: 18570267 [TBL] [Abstract][Full Text] [Related]
19. Long-lasting effect of dexrazoxane against anthracycline cardiotoxicity in rats. Della Torre P; Podesta A; Pinciroli G; Iatropoulos MJ; Mazué G Toxicol Pathol; 1996; 24(4):398-402. PubMed ID: 8864181 [TBL] [Abstract][Full Text] [Related]
20. Enalaprilat increases PPARβ/δ expression, without influence on PPARα and PPARγ, and modulate cardiac function in sub-acute model of daunorubicin-induced cardiomyopathy. Cernecka H; Ochodnicka-Mackovicova K; Kucerova D; Kmecova J; Nemcekova V; Doka G; Kyselovic J; Krenek P; Ochodnicky P; Klimas J Eur J Pharmacol; 2013 Aug; 714(1-3):472-7. PubMed ID: 23834779 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]